Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.

about

Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.

P2860

Q55512944-827FC1A6-5A87-4BC0-8BE5-DE99AC4F0173

P2860

Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.

Item

http://www.wikidata.org/entity/Q39453985

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@en

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@nl

type

Item

label

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@en

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@nl

prefLabel

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@en

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@nl

P1476

Nucleoside reverse transcripta ...... tment: assessing the evidence.

@en

P2093

A Antinori

http://www.w3.org/2001/XMLSchema#string

A Carr

http://www.w3.org/2001/XMLSchema#string

C Orkin

http://www.w3.org/2001/XMLSchema#string

Gmn Behrens

http://www.w3.org/2001/XMLSchema#string

J M Llibre

http://www.w3.org/2001/XMLSchema#string

S Gallien

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.

Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

P31

scholarly article

P356

10.1111/HIV.12534

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28737291

http://www.w3.org/2001/XMLSchema#string

Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.

about

P2860

P2860

Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698